Metabolomic analysis of Mycobacterium tuberculosis reveals metabolic profiles for identification of drug-resistant tuberculosis.

Pratchakan Chaiyachat, Benjawan Kaewseekhao, Angkana Chaiprasert, Phalin Kamolwat, Ditthawat Nonghanphithak, Jutarop Phetcharaburanin, Auttawit Sirichoat, Rick Twee-Hee Ong, Kiatichai Faksri
Author Information
  1. Pratchakan Chaiyachat: Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  2. Benjawan Kaewseekhao: Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  3. Angkana Chaiprasert: Office for Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  4. Phalin Kamolwat: Bureau of Tuberculosis, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
  5. Ditthawat Nonghanphithak: Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  6. Jutarop Phetcharaburanin: Department of Systems Biosciences and Computational Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  7. Auttawit Sirichoat: Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
  8. Rick Twee-Hee Ong: Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
  9. Kiatichai Faksri: Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand. kiatichai@kku.ac.th.

Abstract

The detection of pre-extensively (pre-XDR) and extensively drug-resistant tuberculosis (XDR-TB) is challenging. Drug-susceptibility tests for some anti-TB drugs, especially ethambutol (ETH) and ethionamide (ETO), are problematic due to overlapping thresholds to differentiate between susceptible and resistant phenotypes. We aimed to identify possible metabolomic markers to detect Mycobacterium tuberculosis (Mtb) strains causing pre-XDR and XDR-TB. The metabolic patterns of ETH- and ETO-resistant Mtb isolates were also investigated. Metabolomics of 150 Mtb isolates (54 pre-XDR, 63 XDR-TB and 33 pan-susceptible; pan-S) were investigated. Metabolomics of ETH and ETO phenotypically resistant subgroups were analyzed using UHPLC-ESI-QTOF-MS/MS. Orthogonal partial least-squares discriminant analysis revealed distinct separation in all pairwise comparisons among groups. Two metabolites (meso-hydroxyheme and itaconic anhydride) were able to differentiate the pre-XDR and XDR-TB groups from the pan-S group with 100% sensitivity and 100% specificity. In comparisons of the ETH and ETO phenotypically resistant subsets, sets of increased (ETH = 15, ETO = 7) and decreased (ETH = 1, ETO = 6) metabolites specific for the resistance phenotype of each drug were found. We demonstrated the potential for metabolomics of Mtb to differentiate among types of DR-TB as well as between isolates that were phenotypically resistant to ETO and ETH. Thus, metabolomics might be further applied for DR-TB diagnosis and patient management.

References

  1. Sci Rep. 2018 Mar 20;8(1):4910 [PMID: 29559684]
  2. PLoS Pathog. 2010 Aug 12;6(8):e1000949 [PMID: 20711357]
  3. Trends Biochem Sci. 2017 Mar;42(3):232-242 [PMID: 27839654]
  4. Front Biosci (Elite Ed). 2019 Jan 1;11(1):38-60 [PMID: 30468637]
  5. Nat Commun. 2012 Mar 20;3:753 [PMID: 22434196]
  6. Emerg Infect Dis. 2021 Mar;27(3):813-822 [PMID: 33622486]
  7. Clin Chim Acta. 2018 Aug;483:57-63 [PMID: 29678632]
  8. J Bacteriol. 1992 Jul;174(13):4435-43 [PMID: 1624435]
  9. Int J Antimicrob Agents. 2019 Aug;54(2):109-116 [PMID: 30981926]
  10. Biomark Med. 2017 Feb;11(2):179-194 [PMID: 28097879]
  11. 3 Biotech. 2017 Oct;7(5):325 [PMID: 28955622]
  12. Int J Tuberc Lung Dis. 1998 Jan;2(1):72-89 [PMID: 9562116]
  13. Exp Biol Med (Maywood). 2020 Mar;245(6):501-511 [PMID: 32046521]
  14. Bioinformatics. 2014 Jul 1;30(13):1937-9 [PMID: 24642061]
  15. Anal Chem. 2015 Apr 21;87(8):4184-93 [PMID: 25664760]
  16. Chem Biol. 2011 Dec 23;18(12):1537-49 [PMID: 22195556]
  17. Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3779-84 [PMID: 27006503]
  18. PLoS One. 2020 Dec 31;15(12):e0244829 [PMID: 33382836]
  19. Chem Rev. 2019 Jan 23;119(2):1193-1220 [PMID: 30474981]
  20. Cell Metab. 2007 Nov;6(5):348-51 [PMID: 17983580]
  21. Comput Biol Chem. 2013 Dec;47:167-80 [PMID: 24121675]
  22. Infect Genet Evol. 2021 Dec;96:105142 [PMID: 34800711]
  23. Tuberculosis (Edinb). 2021 Jan;126:102043 [PMID: 33370646]
  24. Biochemistry. 2021 Mar 30;60(12):918-928 [PMID: 33729746]
  25. Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396 [PMID: 34019663]
  26. Microbiol Spectr. 2014 Apr;2(2): [PMID: 26105822]
  27. Bull World Health Organ. 2012 Sep 1;90(9):693-8 [PMID: 22984314]
  28. BMC Infect Dis. 2019 Jun 24;19(1):553 [PMID: 31234780]
  29. PLoS One. 2017 Jan 24;12(1):e0168865 [PMID: 28118372]
  30. Tuberculosis (Edinb). 2020 Dec;125:102004 [PMID: 33017720]
  31. Emerg Microbes Infect. 2022 Dec;11(1):1857-1866 [PMID: 35792049]
  32. Nucleic Acids Res. 2016 Jan 4;44(D1):D471-80 [PMID: 26527732]
  33. BMC Genomics. 2016 Nov 2;17(1):847 [PMID: 27806686]
  34. Inorg Chem. 2014 Jun 16;53(12):5931-40 [PMID: 24901029]
  35. PeerJ. 2019 May 1;7:e6857 [PMID: 31106066]
  36. Cochrane Database Syst Rev. 2022 May 18;5:CD014841 [PMID: 35583175]
  37. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2257-64 [PMID: 26833163]
  38. Microb Genom. 2021 Nov;7(11): [PMID: 34787541]
  39. Chem Biol. 2010 Oct 29;17(10):1122-31 [PMID: 21035735]
  40. Front Cell Infect Microbiol. 2017 Jun 08;7:240 [PMID: 28642844]
  41. Arch Microbiol. 2021 Sep;203(7):3989-3996 [PMID: 34032874]
  42. Pathog Dis. 2018 Jul 1;76(5): [PMID: 29905867]
  43. Ann Lab Med. 2015 Sep;35(5):494-9 [PMID: 26206685]
  44. Sci Rep. 2017 Jul 19;7(1):5860 [PMID: 28725053]
  45. J Neurosci Res. 2017 Oct;95(10):2005-2024 [PMID: 28301062]
  46. J Antimicrob Chemother. 2019 Sep 1;74(9):2605-2616 [PMID: 31119271]

MeSH Term

Humans
Mycobacterium tuberculosis
Antitubercular Agents
Extensively Drug-Resistant Tuberculosis
Tandem Mass Spectrometry
Drug Resistance, Multiple, Bacterial
Tuberculosis, Multidrug-Resistant
Ethionamide
Ethambutol
Metabolome
Microbial Sensitivity Tests

Chemicals

Antitubercular Agents
Ethionamide
Ethambutol

Word Cloud

Created with Highcharts 10.0.0pre-XDRtuberculosisXDR-TBETHETOresistantMtbdifferentiateisolatesphenotypicallydrug-resistantMycobacteriummetabolicinvestigatedMetabolomicspan-Sanalysiscomparisonsamonggroupsmetabolites100%metabolomicsDR-TBdetectionpre-extensivelyextensivelychallengingDrug-susceptibilitytestsanti-TBdrugsespeciallyethambutolethionamideproblematicdueoverlappingthresholdssusceptiblephenotypesaimedidentifypossiblemetabolomicmarkersdetectstrainscausingpatternsETH-ETO-resistantalso150546333pan-susceptiblesubgroupsanalyzedusingUHPLC-ESI-QTOF-MS/MSOrthogonalpartialleast-squaresdiscriminantrevealeddistinctseparationpairwiseTwomeso-hydroxyhemeitaconicanhydrideablegroupsensitivityspecificitysubsetssetsincreasedETH = 15ETO = 7decreasedETH = 1ETO = 6specificresistancephenotypedrugfounddemonstratedpotentialtypeswellThusmightapplieddiagnosispatientmanagementMetabolomicrevealsprofilesidentification

Similar Articles

Cited By (3)